youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
IRWD:NASDAQ
Ironwood Pharmaceuticals, Inc.
$3.46
arrow_downward
-1.14%(-0.040) 1D
$3.49
arrow_upward
+0.87% (+0.030)bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IRWD...
Open
$3.50
High
$3.58
Low
$3.43
Mkt. cap
571.73M
Avg. vol.
1.81M
Volume
24.00
P/E ratio
4.56
52-wk high
$5.78
52-wk low
$1.76
EPS
$0.76
Beta
0.22
Shares outstanding
165.24M
No. of employees
100
Open
$3.50
High
$3.58
Low
$3.43
Mkt. cap
571.73M
Avg. vol.
1.81M
Volume
24.00
P/E ratio
4.56
52-wk high
$5.78
52-wk low
$1.76
EPS
$0.76
Beta
0.22
Shares outstanding
165.24M
No. of employees
100
News stories
From web sources and news partners
The Motley Fool
·
14 minutes ago
The Stock Market Will Make a Big Move in the Next 6 Months if History Repeats Itself
ChartMill
·
41 minutes ago
Acadia Healthcare (NASDAQ:ACHC) Meets a Breakout Setup With Strong Technicals
Yahoo Finance
·
1 hour ago
Broadridge Signs On to Run Shareholder Votes for NYSE’s Planned Tokenized Stocks
Seeking Alpha
·
3 hours ago
The Midterm Election Rally: What 19 Election Cycles Reveal About the S&P 500
Profile
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler's diarrhea.
By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
About Ironwood Pharmaceuticals, Inc.
CEO-
Employees100
Founded1998
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteironwoodpharma.com